Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vertex Pharmaceuticals (VRTX) -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (483)	2/22/2001 9:55:07 PM
From: Miljenko Zuanic	Respond to of 1169

<<Admittedly, if VRTX or anyone else offers a far better drug than ribavirin it will take the sales from ICN/SGP. No company would be happier than Roche to have a replacement for ribavirin. They had to hate what SGP did to them by getting approval "bundled".>> First, from PIIa monotherapy results I was skeptical. Than, as of yesterday (and based on HYPE from VRTX) I did have hope that they have something in hand. Today, I can only say: What the MEDIOCRE, STUPID and NON-COMPETENT management are running this company? 50 pts, 28 days, three arms placebo controlled and they are looking for efficacy (objective response, immunology, sero-conversion, viral clearance,..) ? What they had learned? What was objective? What to do next? Nine months for 28 days study??? <<Cambridge, MA, July 3, 2000 - Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) announced today that patient dosing is underway in a Phase II clinical trial of VX-497, a novel drug for the treatment of hepatitis C virus (HCV) infection, in combination with interferon alpha. HCV infection is a chronic viral disease affecting 2.7 million people in the United States. HCV causes inflammation of the liver, which may lead to cirrhosis, liver failure, and liver cancer. The trial announced today follows the completion of a clinical study assessing the safety and preliminary efficacy of VX-497 as monotherapy for treatment of HCV infection.>> This data were known in SEPTEMBER, and they are still doing analysis??? Is there anyone left for promotion? Ah yes, CFO left. :) I do not want to repeat TTP, but: FACK YOU JOSHUA B.! EXP N! Regards, Miljenko PS: Novel clinical paradigm for Timcodor? What they are discovering? HOT WATER?

To: IRWIN JAMES FRANKEL who wrote (483)	2/22/2001 11:52:15 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1169

>> Could the Vertex drug be the 3rd drug in the Combo? << No, it is (was?) intended to replace the second. However, there are other research programs at VRTX that address the third component (protease inhibitor, helicase inhibitor).